COEPW
Coeptis Therapeutics Holdings, Inc. NASDAQ$0.01
Mkt Cap $44,041
52w Low $0.01
4.5% of range
52w High $0.03
50d MA $0.01
200d MA $0.02
P/E (TTM)
0.0x
EV/EBITDA
-4.6x
P/B
0.0x
Debt/Equity
0.0x
ROE
—
P/FCF
-7.0x
RSI (14)
—
ATR (14)
—
Beta
2.42
50d MA
$0.01
200d MA
$0.02
Avg Volume
64.7K
About
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-D…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | — | -0.28 | — | 0.01 | +23.3% | +22.2% | +94.0% | +49.5% | +48.5% | +51.5% | +1.0% | — |
| Nov 14, 2025 | AMC | — | -0.03 | — | — | — | — | — | — | — | — | — | — |
| Aug 14, 2025 | AMC | — | -0.95 | — | 0.02 | +0.8% | +38.8% | +38.8% | +22.4% | +38.8% | -14.3% | +16.3% | — |
| Jun 30, 2023 | AMC | — | -0.22 | — | — | — | — | — | — | — | — | — | — |
| Dec 31, 2022 | AMC | — | -0.72 | — | — | — | — | — | — | — | — | — | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 17 | EF Hutton | Maintains | Buy → Buy | — | $0.12 | $0.08 | -30.2% | -13.0% | -32.2% | +15.2% | -8.2% | -16.8% |
Recent Filings
Data updated apr 30, 2026 4:20pm
· Source: massive.com